چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده | نفر چندم مقاله |
|---|---|
| حنانه جوزی | اول |
| لاله فخر | دوم |
| علی طریقت اسفنجانی | سوم |
| عنوان | متن |
|---|---|
| خلاصه مقاله | Introduction: Diabetes Mellitus is a chronic metabolic disease and over 90% of cases have type 2 diabetes (T2DM). It is estimated that diabetic patients will reach 700.2 million individuals by 2045. Insulin resistance (IR), improper diet and lifestyle, genetic defects, and inflammation are all the causes of diabetes. Elevated levels of pro-inflammatory cytokine named Interleukin 1 beta (IL-1β) in visceral fat are related to an increased risk of T2DM. Also, Adiponectin, a major peptide released by fat cells, is linked to obesity, insulin resistance, and inflammation, and it drops in obesity-related increased visceral fat individuals. One of the natural supplements used to control complications and treat Diabetes Mellitus is fenugreek (Trigonella foenum-graecum.Linn.) and it is used widely due to its anti-diabetic and anti-inflammatory effects. Also, most of the studies on fenugreek and inflammation were animal and few human studies have been done. On the other hand, several studies have used plant seed powder and not the pure extract, so this study has been conducted. Methods and materials: This research was approved by the Ethics Committee of Tabriz University of Medical Sciences with the ethics code IR.TBZMED.REC.1400.399 and the study protocol has been registered in the Iranian Clinical Trials Registration Center with the code (IRCT20210407050880N1). In this double-blind randomized controlled clinical trial that was conducted for 8 weeks, 46 patients with type 2 diabetes of both genders with an average age of 55 years were randomly assigned by RAS software to two groups: supplement group (n=23) with 335 mg dry fenugreek seed extract or placebo group (n=23) with microcrystalline cellulose. Statistical analysis of the data was done with Wilcoxon, Mann- Whitney, ANCOVA, and Paired samples t-test. Results: At the end of the study, a total of 46 patients completed the study, with 23 patients having been administered fenugreek and the remaining 20 receiving a placebo. There was no statistically significant difference in general characteristics between the two groups of participants at the start of the study. Following an 8-week period of intervention, the results indicated that adiponectin has a marginal decrease (P=0.055) while a notable and statistically significant decline was observed in interleukin levels (P=0.037). Conclusion: Overall, fenugreek can significantly decrease the level of the inflammatory factor IL-1 and increase the non-inflammatory factor adiponectin. Fenugreek can activate the Peroxisome proliferator-activated receptor (PPAR) receptor pathway, which is involved in the regulation of adiponectin expression. Fenugreek, can decrease insulin and increase mRNA expression of PPAR-γ, and serum adiponectin levels due to 4-HIL and diosgenin. Moreover, further research should have done to confirm these results. |
| کلمات کلیدی | fenugreek، inflammation ، diabetic patients |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| cb3fd0a4a229fb1a36197b5712abafc9.jpg | 1403/11/15 | 533431 | دانلود |
| 11.jpg | 1403/11/15 | 160822 | دانلود |
